CryoPort Aktie News

Der Umsatz im zweiten Quartal wuchs im Jahresvergleich um 8 % auf 49,0 Mio. USD Life Sciences Services-Umsatz stieg im Jahresvergleich um 15 % BioStorage/BioServices-Umsatz wuchs im Jahresvergleich um 25 % Unterstützt 779 globale klinische Studien und 22 kommerziell zugelassene Zell- und Gentherapien (CGT) zum 30. Juni 2026 NASHVILLE, Tenn., 6. Aug. 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: ...

IntegriCell Provides Process Development, Technology Transfer, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310 NASHVILLE, Tenn., June 25, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain soluti...

First quarter revenue grew 16% year-over-year to $47.8 million Commercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT programs Life Sciences Services revenue increased 18% year-over-year, led by 21% growth in BioStorage/BioServices  Life Sciences Products revenue increased 15% year-over-year, driven by strong demand...

NASHVILLE, Tenn., April 20, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the first quarter ended March 31, 2026 on Monday, May 4, 2026 after U.S. markets close.